GSK3B and metabolic dysfunction-associated steatohepatitis: Therefore, the inhibitory effect of the CXXC5-Dvl PPI is greater than that of GSK3β on the activation of Wnt/β-catenin signaling and the subsequent therapeutic effects of KY19334 on NASH.